Data on Urothelial Cancer Reported by Aslihan Gerhold-Ay and Colleagues (Aveluma b first-line maintenance in advanced urothelial carcinoma: Complete screening fo r prognostic and predictive factors using machine learning in the JAVELIN Bladder ...)
Data on Urothelial Cancer Reported by Aslihan Gerhold-Ay and Colleagues (Aveluma b first-line maintenance in advanced urothelial carcinoma: Complete screening fo r prognostic and predictive factors using machine learning in the JAVELIN Bladder ...)
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Oncology - Urothelial Cancer is the subject of a report. According to news reporting originating from Darmstadt, Germany, by NewsRx correspondents, research stated, “Avelumab first-l ine (1 L) maintenance is a standard of care for advanced urothelial carcinoma (a UC) based on the JAVELIN Bladder 100 phase 3 trial, which showed that avelumab 1 L maintenance + best supportive care (BSC) significantly prolonged overall surv ival (OS) and progression-free survival (PFS) vs BSC alone in patients who were progression free after receiving 1 L platinum-containing chemotherapy. Here, we comprehensively screened JAVELIN Bladder 100 trial datasets to identify prognost ic factors that define subpopulations of patients with longer or shorter OS irre spective of treatment, and predictive factors that select patients who could obt ain a greater OS benefit from avelumab 1 L maintenance treatment.”
Key words
Darmstadt/Germany/Europe/Avelumab The rapy/Cancer/Carcinomas/Clinical Research/Clinical Trials and Studies/Cyborg s/Drugs and Therapies/Emerging Technologies/Health and Medicine/Immunologic Agents/Immunotherapy/Machine Learning/Monoclonal Antibodies/Oncology/Pharma ceuticals/Urothelial Cancer
NETL
NSTL